# Zanzalintinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zanzalintinib

> The PDUFA target action date for zanzalintinib, sponsored by EXELIXIS, INC. (EXEL), is December 3, 2026, for previously treated metastatic colorectal cancer. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the zanzalintinib PDUFA date?

The PDUFA target action date for zanzalintinib, sponsored by EXELIXIS, INC. (EXEL), is December 3, 2026, for previously treated metastatic colorectal cancer. Status: scheduled. Press release filed with the SEC (EX-99): ""Our first New Drug Application for zanzalintinib, for its initial potential indication in previously treated metastatic colorectal cancer, was accepted by U.S. regulatory authorities and is under active review, with a target action date of December 3, 2026." Last confirmed October 29, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/zanzalintinib)

Source: Press release filed with the SEC (EX-99), accession 0000939767-26-000058, https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/pdufa/zanzalintinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | zanzalintinib |
| Codes | XL092 |
| Sponsor | EXELIXIS, INC. (EXEL) https://sec-api.dev/companies/exel/catalysts |
| Indications | recurrent grade i/ii/iii meningioma with relapse or progression, previously treated metastatic colorectal cancer, with previously treated metastatic crc, resected stage ii/iii crc, with metastatic crc, metastatic crc, when used in combination with atezolizumab, [Meningioma](https://sec-api.dev/indications/meningioma), [Colorectal Cancer](https://sec-api.dev/indications/colorectal-cancer) |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### 1H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3. Indication: advanced NET, regardless of site of origin.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000004): "•Exelixis also expects to initiate STELLAR-311, a phase 3 pivotal trial evaluating zanzalintinib compared with everolimus as a first oral therapy in patients with advanced NET, regardless of site of origin, in the first half of 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000004/exel20250112exhibit991.htm

### 1H 2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1/2.
- First seen 2025-01-13, last confirmed 2025-05-13.
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000004): "Exelixis' expectation for initial clinical data readouts from STELLAR-001 and STELLAR-002 in 2025 and the presentation of data from STELLAR-001 at ASCO GI 2025" https://www.sec.gov/Archives/edgar/data/939767/000093976725000004/exel20250112exhibit991.htm
- SEC Form 10-Q (accession 0000939767-25-000075): "We anticipate initial clinical data readouts from STELLAR-002 in the first half of 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000075/exel-20250404.htm
- SEC Form 10-K (accession 0000939767-25-000019): "We anticipate initial clinical data readouts from STELLAR-002 in the first half of 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000019/exel-20250103.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000004): "Exelixis anticipates initial clinical data readouts from zanzalintinib's phase 1b/2 STELLAR-001 and STELLAR-002 clinical studies in the first half of 2025, including data from CRC and RCC cohorts." https://www.sec.gov/Archives/edgar/data/939767/000093976725000004/exel20250112exhibit991.htm

### Jun 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-07-28, last confirmed 2026-02-10.
- SEC Form 10-K (accession 0000939767-26-000021): "•In June 2025, we announced positive top-line results from the STELLAR-303 phase 3 pivotal trial that the study met one of its dual primary endpoints, OS in the ITT population, with the OS benefit of the zanzalintinib and atezolizumab combination consistently observed across pre-specified subgroups." https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm
- SEC Form 10-Q (accession 0000939767-25-000113): "•In June 2025, we announced positive top-line results from STELLAR-303 in which zanzalintinib in combination with atezolizumab demonstrated a statistically significant improvement in OS versus regorafenib in the ITT population of patients with previously treated non-MSI-H/dMMR CRC." https://www.sec.gov/Archives/edgar/data/939767/000093976725000113/exel-20250704.htm

### July 28, 2025: trial start

- Status: completed. Date confidence: exact.
- First seen 2025-07-28, last confirmed 2025-07-28.
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000111): "We also initiated the STELLAR-311 pivotal study in advanced NET during the quarter and plan to announce an additional wave of zanzalintinib pivotal trials in the coming months." https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/exel20250630exhibit991.htm

### late 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half. Indication: with previously treated metastatic CRC.
- First seen 2025-11-04, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000127): "Based on these findings, Exelixis intends to submit a New Drug Application for zanzalintinib in combination with atezolizumab for the treatment of patients with previously treated metastatic CRC in the U.S. by the end of 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/exel20250930exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000127): "This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis' plans to submit a New Drug Application for zanzalintinib in combination with atezolizumab for the treatment of patients with previously treated metastatic CRC in the U.S. by the end of 2025, which is subject to limitations on the availability of government services, such as from the FDA, as a result of the ongoing U.S. federal government shutdown" https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/exel20250930exhibit991.htm

### Dec 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-02-10, last confirmed 2026-02-10.
- SEC Form 10-K (accession 0000939767-26-000021): "We submitted our first NDA to the FDA for zanzalintinib in December 2025." https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-07-28, last confirmed 2025-07-28.
- Press release filed with the SEC (EX-99) (accession 0000939767-25-000111): "In May, we completed enrollment into the STELLAR-304 pivotal study in non-clear cell renal cell carcinoma with top-line results expected in the first half of 2026, depending on study event rates." https://www.sec.gov/Archives/edgar/data/939767/000093976725000111/exel20250630exhibit991.htm

### February 10, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Stage: 3. Indication: previously treated metastatic CRC, when used in combination with atezolizumab.
- First seen 2026-02-10, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000019): "In February 2026, Exelixis announced that the FDA accepted its NDA for zanzalintinib as a treatment for patients with previously treated metastatic CRC, when used in combination with atezolizumab." https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000096): "In February 2026, the U.S. FDA accepted the company's NDA for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic CRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy." https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000058): "In February 2026, Exelixis announced that the U.S. FDA accepted its NDA for zanzalintinib as a treatment for patients with metastatic CRC, when used in combination with atezolizumab." https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm
- SEC Form 10-Q (accession 0000939767-26-000059): "•In February 2026, we announced that the FDA accepted our NDA for zanzalintinib in combination with atezolizumab for the treatment of previously treated metastatic colorectal cancer, based on positive results from the STELLAR-303 phase 3 pivotal trial, and had assigned a standard review, with a PDUFA target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm

### mid-2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-01-12, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000096): "Exelixis remains on track to initiate the planned phase 3 STELLAR-316 pivotal trial of zanzalintinib in mid-2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000003): "Exelixis expects to initiate STELLAR-201 in mid-2026, and a confirmatory phase 3 study is also being planned." https://www.sec.gov/Archives/edgar/data/939767/000093976726000003/exel20260111exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000019): "Exelixis' anticipated timing for pivotal data milestones for the STELLAR-303 and STELLAR-304 trials and plans to initiate additional zanzalintinib pivotal trials in 2026, including STELLAR-316 and STELLAR-201" https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm

### May 5, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 2. Indication: recurrent Grade I/II/III meningioma with relapse or progression.
- First seen 2026-05-05, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000058): "Today, Exelixis announced it has initiated STELLAR-201, a phase 2 trial evaluating zanzalintinib in patients with recurrent Grade I/II/III meningioma with relapse or progression following radiation and/or surgery or those who are not candidates for these therapies." https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm
- SEC Form 10-Q (accession 0000939767-26-000116): "In April 2026, we initiated STELLAR-201, a phase 2 trial evaluating zanzalintinib in patients with recurrent Grade I/II/III meningioma with relapse or progression following radiation and/or surgery or those who are not candidates for these therapies." https://www.sec.gov/Archives/edgar/data/939767/000093976726000116/exel-20261002.htm
- SEC Form 10-Q (accession 0000939767-26-000098): "In April 2026, we initiated STELLAR-201, a phase 2 trial evaluating zanzalintinib in patients with recurrent Grade I/II/III meningioma with relapse or progression following radiation and/or surgery or those who are not candidates for these therapies." https://www.sec.gov/Archives/edgar/data/939767/000093976726000098/exel-20260703.htm
- SEC Form 10-Q (accession 0000939767-26-000098): "•In April 2026, we initiated STELLAR-201, a phase 2 trial evaluating zanzalintinib in patients with recurrent Grade I/II/III meningioma with relapse or progression following radiation and/or surgery or those who are not candidates for radiation and/or surgery." https://www.sec.gov/Archives/edgar/data/939767/000093976726000098/exel-20260703.htm
- SEC Form 10-Q (accession 0000939767-26-000059): "In April 2026, we initiated STELLAR-201, a phase 2 trial evaluating zanzalintinib in patients with recurrent Grade I/II/III meningioma with relapse or progression following radiation and/or surgery or those who are not candidates for these therapies." https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm
- SEC Form 10-Q (accession 0000939767-26-000059): "•In April 2026, we initiated STELLAR-201, a phase 2 trial evaluating zanzalintinib in patients with recurrent Grade I/II/III meningioma with relapse or progression following radiation and/or surgery or those who are not candidates for radiation and/or surgery." https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000096): "In April 2026, Exelixis' collaborator Merck initiated LITESPARK-034, a global phase 3 pivotal trial evaluating zanzalintinib in combination with WELIREG® (belzutifan) versus WELIREG and placebo in second-line or later advanced renal cell carcinoma (RCC) patients who have progressed on or after both programmed death-1/ligand 1 (PD-1/L1) and vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapies in sequence or in combination." https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000058): "In April 2026, Exelixis' collaborator Merck, known as MSD outside of the United States and Canada, initiated LITESPARK-034, a global phase 3 pivotal trial evaluating zanzalintinib in combination with WELIREG® (belzutifan) versus WELIREG and placebo in second-line or later advanced RCC patients who have progressed on or after both programmed death-ligand 1 (PD-1/L1) and vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapies in sequence or in combination." https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-02-10, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000019): "anticipated topline results from STELLAR-304, the phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously untreated patients with advanced non-clear cell RCC, in mid-2026, based on current event rates" https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000096): "Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in Second Half of 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000058): "Topline Results for STELLAR-304 Phase 3 Pivotal Trial Expected in Second Half of 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm

### Aug 2026: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: resected stage II/III CRC.
- First seen 2026-10-29, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000114): "In August 2026, Exelixis initiated the phase 3 STELLAR-316 pivotal trial evaluating zanzalintinib, with and without KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), in patients with resected stage II/III CRC who," https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm

### December 3, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 3. Indication: previously treated metastatic colorectal cancer.
- First seen 2026-02-10, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000058): ""Our first New Drug Application for zanzalintinib, for its initial potential indication in previously treated metastatic colorectal cancer, was accepted by U.S. regulatory authorities and is under active review, with a target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm
- SEC Form 10-Q (accession 0000939767-26-000059): "•In February 2026, we announced that the FDA accepted our NDA for zanzalintinib in combination with atezolizumab for the treatment of previously treated metastatic colorectal cancer, based on positive results from the STELLAR-303 phase 3 pivotal trial, and had assigned a standard review, with a PDUFA target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000096): "The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000058): "The FDA assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000019): "The FDA assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm
- SEC Form 10-Q (accession 0000939767-26-000116): "In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000116/exel-20261002.htm
- SEC Form 10-Q (accession 0000939767-26-000098): "In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000098/exel-20260703.htm
- SEC Form 10-Q (accession 0000939767-26-000059): "Table of Contents that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm
- SEC Form 10-K (accession 0000939767-26-000021): "In January 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm
- SEC Form 10-K (accession 0000939767-26-000021): "In January 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a PDUFA target action date of December 3, 2026." https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-10-29, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000114): "Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in First Quarter of 2027." https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm

### March 3, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-09-11, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000114): "Ongoing Regulatory Review of Zanzalintinib in Combination with Atezolizumab (Tecentriq®) for Previously Treated Metastatic CRC with Prescription Drug User Fee Act (PDUFA) Target Action Date of March 3, 2027." https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0000939767-26-000114): "The updated PDUFA target action date is March 3, 2027." https://www.sec.gov/Archives/edgar/data/939767/000093976726000114/exel20260930exhibit991.htm
- SEC Form 8-K (accession 0000939767-26-000108): "The updated Prescription Drug User Fee Act action date is March 3, 2027." https://www.sec.gov/Archives/edgar/data/939767/000093976726000108/exel-20260910.htm

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Meningioma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07428616 (A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Exelixis." https://clinicaltrials.gov/study/NCT07428616

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Meningioma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07428616 (A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-29 (ESTIMATED); Lead Sponsor Exelixis." https://clinicaltrials.gov/study/NCT07428616

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Head and Neck Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06082167 (Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Exelixis." https://clinicaltrials.gov/study/NCT06082167

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Head and Neck Squamous Cell Carcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06082167 (Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Exelixis." https://clinicaltrials.gov/study/NCT06082167

### Jun to Sep 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06943755 (Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor Exelixis." https://clinicaltrials.gov/study/NCT06943755

### June 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06943755 (Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor Exelixis." https://clinicaltrials.gov/study/NCT06943755

### Apr to Jul 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07750158 (Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-05 (ESTIMATED); Lead Sponsor Exelixis." https://clinicaltrials.gov/study/NCT07750158

### April 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07750158 (Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-05 (ESTIMATED); Lead Sponsor Exelixis." https://clinicaltrials.gov/study/NCT07750158

## Same indication

- [Evorpacept](https://sec-api.dev/pdufa/evorpacept) (ALXO)
- [JZP3507](https://sec-api.dev/pdufa/jzp3507) (JAZZ)
- [Petosemtamab](https://sec-api.dev/pdufa/petosemtamab) (GMAB)
- [Telisotuzumab adizutecan](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) (ABBV)
- [VS-7375](https://sec-api.dev/pdufa/vs-7375) (VSTM)
- [XL092](https://sec-api.dev/pdufa/xl092) (EXEL)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12), [March 2027](https://sec-api.dev/fda-calendar/2027-03), [February 2028](https://sec-api.dev/fda-calendar/2028-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zanzalintinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zanzalintinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zanzalintinib

```bibtex
@misc{secapidev_pdufa_zanzalintinib_20261116,
  title        = {Zanzalintinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zanzalintinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zanzalintinib_20261116","title":"Zanzalintinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zanzalintinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
